Biosplice Therapeutics Valuation Estimate
Biosplice Therapeutics Valuation as of Last Funding Round
Biosplice Therapeutics Company Overview
Established in 2009 by Osman Kibar, Biosplice's mission is to restore health by providing the finest medicines based on alternative splicing. Their scientific platform is based on biological discoveries that govern tissue specialization. It enables them to eliminate harmful proteins using small molecules selectively. Biosplice's primary focuses are on treatments for osteoarthritis and oncology. However, they are also in the early stages of developing programs in neurology and other areas.
Biosplice Therapeutics Valuation History
Biosplice Therapeutics Stock Price
The stock price of Biosplice Therapeutics can be calculated by taking the valuation of the company divided by the number of shares outstanding. Because a private company can issue new shares at any time, we do not know the current number of shares outstanding.
For illustrative purposes, however, assuming Biosplice Therapeutics has issued 250 million shares, at the estimated UpMarket valuation of $11.80 billion, each share of Biosplice Therapeutics stock would be worth $47.18.
Buy Biosplice Therapeutics Stock
If you would like to buy shares in Biosplice Therapeutics, please provide your information in the form at the top of this page and click the button titled “I want to buy this stock.”
One of our investor relations team members will contact you to discuss Biosplice Therapeutics stock availability. Note: inquiries are non-binding and shares may only be purchased by accredited investors that meet all eligibility criteria.
UpMarket has offered many similar companies as Pre-IPO investments, including Airbnb, SpaceX, ByteDance, Plaid, Kraken, Databricks, and others. UpMarket also often has funds available that invest in a portfolio of companies potentially including, Biosplice Therapeutics as well.
Biosplice Therapeutics Management